Macada Holding, Inc. Reports Progress Under New Management

  Macada Holding, Inc. (PINKSHEETS: MCDA) today announced the signing of a financing agreement and provided guidance on the outlook and the vision of the Company under its new Chairman and President.

Macada has signed a letter of intent with Manhattan Capital Corp., LLC for Manhattan to provide to $3 million in financing over the next two years. Completion of the proposed transaction is subject to numerous contingencies, including due diligence and approval of counsel.

Macada's new CEO and Chairman, Ron Ritter, also provided guidance on the progress of the Company and its focus under his leadership. "I believe there is a solid start for our new structure and our Bio-Skin line. I feel confident that the new lotions and products will start to be profitable by the end of September and our 4th quarter will be strong and growing."

Mr. Ritter continued, "Macada is poised to move rapidly with streamlined management, manufacturing, delivery and marketing. The more you see all the pieces in place, the more you can start to predict growth will be rapid and profitable, possibly allowing for further expansion and absorption of other companies that need innovation in these areas."

Macada Holding (PINKSHEETS: MCDA) has a new vision to reshape the conventional notions in the manufacturing industry. The new executive team brings fresh perspective to a company and industries in this economy that have heretofore struggled to find ways to appeal to the huge world wide consumer market. Macada Holding has been restructured with a vision to bring together a comprehensive range of products with manufacturing, marketing and delivery capabilities, utilizing the latest technologies available. Macada Holdings will start to bring fresh revenues to under-utilized markets.

"The first sector we favor is the medical skin care market where we have found some niche arenas," said Mr. Ritter. "You may be surprised to discover how innovative our medical formulas are. They were created to treat various skin ailments in a massive industry that needs results. Changes will occur with the launching of Bio-Skin treatments. It is easy to envision this as a rapid growth line with multiple income streams. We see this division is poised to flourish in the 3rd and 4th quarter of 2010."

"The second sector we favor is the firearms industry, particularly the start-up and expansion of an ammunition manufacturing plant. The demand for quality ammunition in the United States and globally has continued to rise and last year as the industry enjoyed massive growth and profitability," continued Mr. Ritter. "Local demographics will easily absorb the initial production and our expansion to national and the military markets will be swift. We predict sales and profits will be stable with continual and rapid growth."

Macada Market News and Highlights

Macada looks to exploit these large arms and medical markets. The skin disease treatment companies have been spoiled by their tremendous recent successes, and have consequently overlooked some potentially hugely lucrative opportunities. Currently, approximately 50% of all skin diseases patients are not receiving treatment that helps or works in their situation. LyfeTec has been testing Bio-Skin samples and is extremely impressed with the results of its new formulas.

New mothers will be pleased to find that LyfeTec will launch a new product to help newborns with the condition of "cradle cap." LyfeTec's new Bio-Skin line and its cradle cap product will be uniquely positioned to cater to and capitalize on this demand.

The firearms industry has undergone radical transformation and experienced exponential growth in recent years. Macada Holding has benefited from this expansion and has had its business model validated by recent performance. In March of 2009, Macada acquired Pembroke Gun and Range and since then Pembroke has received more visitors and profits in the last five months than in the previous last two years combined. This greatly increases the Macada's results.

Macada Holdings Subsidiary LyfeTec has been working diligently with the laboratory that supplies LyfeTec's samples and products. This supplier offers Macada a turn key solution which benefits LyfeTec demands to have a high end product with results, testing and packaging, from an FDA-approved facility.

"We believe that by the end of the year, having achieved increasing results in sales and earnings, we can look back on all this and see how it produced surprising growth. That is what we are all here for, isn't it?" said Mr. Ritter.

Safe Harbor Provision

This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Macada Holding, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, the availability of technical personnel, changes in technology and competition.

Contact: Ron Ritter Chairman and CEO [e-mail] Steven Cohen President MCDA -- MACADA HOLDING, INC. 4701 N. Federal HWY, Ste 430 Pompano Beach, FL 33264 www.bio-skin.us www.lyfetec.com www.lyfepet.com [e-mail] 954-960-5079